Page 5 of 6
ACS Medicinal Chemistry Letters
1.
Sridharan, V.; Suryavanshi, P. A.; Menendez, J. C.
20.
Gruzdev, D.; Vakarov, S.; Levit, G.; Krasnov, V. NꢀTosylꢀ
Advances in the chemistry of tetrahydroquinolines. Chem. Rev. 2011,
111, 7157ꢀ259.
(S)ꢀProlyl Chloride in Kinetic Resolution of Racemic Heterocyclic
Amines. Chem. Heterocycl. Compounds 2014, 49.
1
2
3
4
5
6
7
8
2.
Courilleau, D.; Bisserier, M.; Jullian, J.ꢀC.; Lucas, A.;
21.
Wiberg, K. B.; Rush, D. J. Solvent effects on the thioamide
Bouyssou, P.; Fischmeister, R.; Blondeau, J.ꢀP.; Lezoualc'h, F.
Identification of a tetrahydroquinoline analog as a pharmacological
inhibitor of the cAMPꢀbinding protein Epac. J. Biol. Chem. 2012,
287, 44192ꢀ44202.
rotational barrier: An experimental and theoretical study. J. Am.
Chem. Soc. 2001, 123, 2038ꢀ2046.
22.
Wiberg, K. B.; Breneman, C. M. Resonance interactions in
acyclic systems. 3. Formamide internal rotation revisited. Charge and
energy redistribution along the CN bond rotational pathway. J. Am.
Chem. Soc 1992, 114, 831ꢀ840.
3.
Courilleau, D.; Bouyssou, P.; Fischmeister, R.; Lezoualc’h,
F.; Blondeau, J.ꢀP. The (R)ꢀenantiomer of CE3F4 is a preferential
inhibitor of human exchange protein directly activated by cyclic AMP
isoform 1 (Epac1). Biochem. Biophys. Res. Commun. 2013, 440, 443ꢀ
448.
23.
Rablen, P. R.; Miller, D. A.; Bullock, V. R.; Hutchinson, P.
9
H.; Gorman, J. A. Solvent Effects on the Barrier to C− N Bond
Rotation in N, NꢀDimethylaminoacrylonitrile. J. Am. Chem. Soc.
1999, 121, 218ꢀ226.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4.
Lezoualc'h, F.; Fischmeister, R.; Bisserier, M.; Bouyssou,
P.; Blondeau, J. P.; Courilleau, D. Tetrahydroquinoline derivatives
and their use as epac inhibitors. US 20150252002A1, 2015.
24.
Hu, D. X.; Grice, P.; Ley, S. V. Rotamers or
diastereomers? An overlooked NMR solution. The J. Org. Chem
2012, 77, 5198ꢀ5202.
25.
Gawrisch, K.; Lee, Y.ꢀS. Z and E rotamers of Nꢀformylꢀ1ꢀbromoꢀ4ꢀ
hydroxyꢀ3ꢀmethoxymorphinanꢀ6ꢀone and their interconversion as
studied by (1)H/(13)C NMR spectroscopy and quantum chemical
calculations. Magn. Reson. Chem. MRC 2013, 51, 82ꢀ88.
5.
Tsalkova, T.; Mei, F. C.; Cheng, X. A fluorescenceꢀbased
highꢀthroughput assay for the discovery of exchange protein directly
activated by cyclic AMP (EPAC) antagonists. PLoS One 2012, 7,
e30441.
Sulima, A.; Cheng, K.; Jacobson, A. E.; Rice, K. C.;
6.
Cheng, X.; Ji, Z.; Tsalkova, T.; Mei, F. Epac and PKA: a
tale of two intracellular cAMP receptors. Acta Biochim Biophys. Sin.
2008, 40, 651ꢀ662.
26.
Olszewska, T.; Pyszno, A.; Milewska, M. J.; Gdaniec, M.;
7.
Grandoch, M.; Roscioni, S. S.; Schmidt, M. The role of
Połoński, T. Thioamides and selenoamides with chirality solely due to
hindered rotation about the C–N bond: enantioselective complexation
with optically active hosts. Tetrahedron: Asymmetry 2005, 16, 3711ꢀ
Epac proteins, novel cAMP mediators, in the regulation of immune,
lung and neuronal function. Br. J. Pharmacol. 2010, 159, 265ꢀ284.
8.
Schmidt, M.; Dekker, F. J.; Maarsingh, H. Exchange
3717
.
protein directly activated by cAMP (epac): a multidomain cAMP
mediator in the regulation of diverse biological functions. Pharmacol.
Rev. 2013, 65, 670ꢀ709.
9.
Laurent, A.ꢀC.; Bisserier, M.; Lucas, A.; Tortosa, F.;
Roumieux, M.; De Régibus, A.; Swiader, A.; SainteꢀMarie, Y.;
Heymes, C.; Vindis, C. Exchange protein directly activated by cAMP
1
promotes autophagy during cardiomyocyte hypertrophy.
Cardiovasc. Res. 2015, 105, 55ꢀ64.
10.
Almahariq, M.; Tsalkova, T.; Mei, F. C.; Chen, H.; Zhou,
J.; Sastry, S. K.; Schwede, F.; Cheng, X. A novel EPACꢀspecific
inhibitor suppresses pancreatic cancer cell migration and invasion.
Mol. Pharmacol. 2013, 83, 122ꢀ128.
11.
Lorenz, R.; Aleksic, T.; Wagner, M.; Adler, G.; Weber, C.
K. The cAMP/Epac1/Rap1 pathway in pancreatic carcinoma.
Pancreas 2008, 37, 102ꢀ103.
12.
Chen, H.; Wild, C.; Zhou, X.; Ye, N.; Cheng, X.; Zhou, J.
Recent Advances in the Discovery of Small Molecules Targeting
Exchange Proteins Directly Activated by cAMP (EPAC). J. Med.
Chem. 2014, 57, 3651ꢀ3665.
13.
prostate cancer. Genes & Develop. 2000, 14, 2410ꢀ2434.
14. Grandoch, M.; Rose, A.; Ter Braak, M.; Jendrossek, V.;
AbateꢀShen, C.; Shen, M. M. Molecular genetics of
Rübben, H.; Fischer, J.; Schmidt, M.; Weber, A. Epac inhibits
migration and proliferation of human prostate carcinoma cells. Br. J.
Cancer 2009, 101, 2038.
15.
Kumar, N.; Gupta, S.; Dabral, S.; Singh, S.; Sehrawat, S.
Role of exchange protein directly activated by cAMP (EPAC1) in
breast cancer cell migration and apoptosis. Mol. Cell. Biochem. 2017,
1ꢀ11.
16.
Holz, G. G.; Chepurny, O. G.; Schwede, F. Epacꢀselective
cAMP analogs: new tools with which to evaluate the signal
transduction properties of cAMPꢀregulated guanine nucleotide
exchange factors. Cell. Signalling 2008, 20, 10ꢀ20.
17.
Tsalkova, T.; Mei, F. C.; Li, S.; Chepurny, O. G.; Leech, C.
A.; Liu, T.; Holz, G. G.; Woods, V. L.; Cheng, X. Isoformꢀspecific
antagonists of exchange proteins directly activated by cAMP. Proc.
Natl. Acad. Sci. U. S. A. 2012, 109, 18613ꢀ18618.
18.
Bouyssou, P.; Le Goff, C.; Chenault, J. Synthesis of 7‐and
5, 7‐substituted‐6‐fluoro‐2‐methyl‐1, 2, 3, 4‐tetrahydroquinolines:
Convenient precursors of quinolone antibacterial agents. J. Heterocl.
Chem. 1992, 29, 895ꢀ898.
19.
Zhu, Y.; Chen, H.; Boulton, S.; Mei, F.; Ye, N.; Melacini,
G.; Zhou, J.; Cheng, X. Biochemical and pharmacological
characterizations of ESIꢀ09 based EPAC inhibitors: Defining the ESIꢀ
09 “therapeutic window”. Sci. Rep. 2015, 5, 9344.
5
ACS Paragon Plus Environment